Molecular mechanisms of loss of β2-microglobulin expression in drug- resistant breast cancer sublines and its involvement in drug resistance

Besim Ogretmen, Mary D. McCauley, Ahmad Safa

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

In this study, we investigated the mechanism of the loss or decreased expression of β2-microglobulin (β2m) in several drug-resistant sublines of MCF-7 and in a doxorubicin (DOX)-resistant variant of the T-47D breast cancer cell line. β2m protein and RNA are not expressed in highly metastatic, multidrug-resistant MCF-7/Adr cells with high resistance to DOX. Nuclear run-on transcription and RNA stability assays demonstrate that while β2m in MCF-7/Adr cells is transcribed, its mRNA is rapidly degraded after synthesis in these cells, indicating that it is controlled by post- transcriptional mechanisms. We also show that an MCF-7 subline (MCF-7/Adr-5) expressing a very low level of resistance to DOX has a decreased level of β2m expression. Treatment with actinomycin D revealed that the half-life of β2m mRNA in MCF-7 and MCF-7/Adr-5 cell lines was comparable. Nuclear run- on transcription analysis revealed a decreased rate of β2m transcription in MCF-7/Adr-5 cells compared to that in MCF-7 cells. Moreover, β2m mRNA remained undetectable in MCF-7/Adr cells following cycloheximide treatment. However, in MCF-7 cells, increased β2m mRNA was observed after 12 h, and a similar level of increased mRNA expression was observed after 36 h of cycloheximide treatment in MCF-7/Adr-5 cells; these results suggest that one of the mechanisms controlling β2m mRNA expression might be a negative regulatory protein in MCF-7/Adr-5 cells. Analysis of the β2m status of other drug-resistant MCF-7 sublines revealed that deregulation of β2m is not limited to DOX resistance, but can also be detected in cells selected for resistance to mAMSA and DOX-verapamil. In addition, our data show that reduced β2m expression correlates with the decreased levels of estrogen receptor (ER) expression in the DOX-resistant MCF-7/Adr and T-47D/Adr-4 human breast cell lines. Furthermore, we provide evidence that the partial inhibition of β2m by antisense RNA results in 2,3-fold decreased sensitivity of MCF-7 cells to DOX and mAMSA. Moreover, the addition of exogenous β2m protein near its physiological human serum concentration can modulate the DOX sensitivity of the MCF-7 antisense β2m and control transfectants. Therefore, these results indicate that lost or decreased β2m expression is involved in the development of the drug-resistant phenotype and correlates with the loss of ER in human breast cancer cell lines.

Original languageEnglish (US)
Pages (from-to)11679-11691
Number of pages13
JournalBiochemistry
Volume37
Issue number33
DOIs
StatePublished - Aug 18 1998
Externally publishedYes

Fingerprint

Drug Resistance
Doxorubicin
MCF-7 Cells
Breast Neoplasms
Pharmaceutical Preparations
Messenger RNA
Transcription
Cells
Cell Line
Cycloheximide
Estrogen Receptors
RNA
Antisense RNA
Proteins
Deregulation
RNA Stability
Dactinomycin
Verapamil
Half-Life
Assays

ASJC Scopus subject areas

  • Biochemistry

Cite this

Molecular mechanisms of loss of β2-microglobulin expression in drug- resistant breast cancer sublines and its involvement in drug resistance. / Ogretmen, Besim; McCauley, Mary D.; Safa, Ahmad.

In: Biochemistry, Vol. 37, No. 33, 18.08.1998, p. 11679-11691.

Research output: Contribution to journalArticle

@article{91c5d513dc7a457abbcbb9997a72e311,
title = "Molecular mechanisms of loss of β2-microglobulin expression in drug- resistant breast cancer sublines and its involvement in drug resistance",
abstract = "In this study, we investigated the mechanism of the loss or decreased expression of β2-microglobulin (β2m) in several drug-resistant sublines of MCF-7 and in a doxorubicin (DOX)-resistant variant of the T-47D breast cancer cell line. β2m protein and RNA are not expressed in highly metastatic, multidrug-resistant MCF-7/Adr cells with high resistance to DOX. Nuclear run-on transcription and RNA stability assays demonstrate that while β2m in MCF-7/Adr cells is transcribed, its mRNA is rapidly degraded after synthesis in these cells, indicating that it is controlled by post- transcriptional mechanisms. We also show that an MCF-7 subline (MCF-7/Adr-5) expressing a very low level of resistance to DOX has a decreased level of β2m expression. Treatment with actinomycin D revealed that the half-life of β2m mRNA in MCF-7 and MCF-7/Adr-5 cell lines was comparable. Nuclear run- on transcription analysis revealed a decreased rate of β2m transcription in MCF-7/Adr-5 cells compared to that in MCF-7 cells. Moreover, β2m mRNA remained undetectable in MCF-7/Adr cells following cycloheximide treatment. However, in MCF-7 cells, increased β2m mRNA was observed after 12 h, and a similar level of increased mRNA expression was observed after 36 h of cycloheximide treatment in MCF-7/Adr-5 cells; these results suggest that one of the mechanisms controlling β2m mRNA expression might be a negative regulatory protein in MCF-7/Adr-5 cells. Analysis of the β2m status of other drug-resistant MCF-7 sublines revealed that deregulation of β2m is not limited to DOX resistance, but can also be detected in cells selected for resistance to mAMSA and DOX-verapamil. In addition, our data show that reduced β2m expression correlates with the decreased levels of estrogen receptor (ER) expression in the DOX-resistant MCF-7/Adr and T-47D/Adr-4 human breast cell lines. Furthermore, we provide evidence that the partial inhibition of β2m by antisense RNA results in 2,3-fold decreased sensitivity of MCF-7 cells to DOX and mAMSA. Moreover, the addition of exogenous β2m protein near its physiological human serum concentration can modulate the DOX sensitivity of the MCF-7 antisense β2m and control transfectants. Therefore, these results indicate that lost or decreased β2m expression is involved in the development of the drug-resistant phenotype and correlates with the loss of ER in human breast cancer cell lines.",
author = "Besim Ogretmen and McCauley, {Mary D.} and Ahmad Safa",
year = "1998",
month = "8",
day = "18",
doi = "10.1021/bi980573c",
language = "English (US)",
volume = "37",
pages = "11679--11691",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "33",

}

TY - JOUR

T1 - Molecular mechanisms of loss of β2-microglobulin expression in drug- resistant breast cancer sublines and its involvement in drug resistance

AU - Ogretmen, Besim

AU - McCauley, Mary D.

AU - Safa, Ahmad

PY - 1998/8/18

Y1 - 1998/8/18

N2 - In this study, we investigated the mechanism of the loss or decreased expression of β2-microglobulin (β2m) in several drug-resistant sublines of MCF-7 and in a doxorubicin (DOX)-resistant variant of the T-47D breast cancer cell line. β2m protein and RNA are not expressed in highly metastatic, multidrug-resistant MCF-7/Adr cells with high resistance to DOX. Nuclear run-on transcription and RNA stability assays demonstrate that while β2m in MCF-7/Adr cells is transcribed, its mRNA is rapidly degraded after synthesis in these cells, indicating that it is controlled by post- transcriptional mechanisms. We also show that an MCF-7 subline (MCF-7/Adr-5) expressing a very low level of resistance to DOX has a decreased level of β2m expression. Treatment with actinomycin D revealed that the half-life of β2m mRNA in MCF-7 and MCF-7/Adr-5 cell lines was comparable. Nuclear run- on transcription analysis revealed a decreased rate of β2m transcription in MCF-7/Adr-5 cells compared to that in MCF-7 cells. Moreover, β2m mRNA remained undetectable in MCF-7/Adr cells following cycloheximide treatment. However, in MCF-7 cells, increased β2m mRNA was observed after 12 h, and a similar level of increased mRNA expression was observed after 36 h of cycloheximide treatment in MCF-7/Adr-5 cells; these results suggest that one of the mechanisms controlling β2m mRNA expression might be a negative regulatory protein in MCF-7/Adr-5 cells. Analysis of the β2m status of other drug-resistant MCF-7 sublines revealed that deregulation of β2m is not limited to DOX resistance, but can also be detected in cells selected for resistance to mAMSA and DOX-verapamil. In addition, our data show that reduced β2m expression correlates with the decreased levels of estrogen receptor (ER) expression in the DOX-resistant MCF-7/Adr and T-47D/Adr-4 human breast cell lines. Furthermore, we provide evidence that the partial inhibition of β2m by antisense RNA results in 2,3-fold decreased sensitivity of MCF-7 cells to DOX and mAMSA. Moreover, the addition of exogenous β2m protein near its physiological human serum concentration can modulate the DOX sensitivity of the MCF-7 antisense β2m and control transfectants. Therefore, these results indicate that lost or decreased β2m expression is involved in the development of the drug-resistant phenotype and correlates with the loss of ER in human breast cancer cell lines.

AB - In this study, we investigated the mechanism of the loss or decreased expression of β2-microglobulin (β2m) in several drug-resistant sublines of MCF-7 and in a doxorubicin (DOX)-resistant variant of the T-47D breast cancer cell line. β2m protein and RNA are not expressed in highly metastatic, multidrug-resistant MCF-7/Adr cells with high resistance to DOX. Nuclear run-on transcription and RNA stability assays demonstrate that while β2m in MCF-7/Adr cells is transcribed, its mRNA is rapidly degraded after synthesis in these cells, indicating that it is controlled by post- transcriptional mechanisms. We also show that an MCF-7 subline (MCF-7/Adr-5) expressing a very low level of resistance to DOX has a decreased level of β2m expression. Treatment with actinomycin D revealed that the half-life of β2m mRNA in MCF-7 and MCF-7/Adr-5 cell lines was comparable. Nuclear run- on transcription analysis revealed a decreased rate of β2m transcription in MCF-7/Adr-5 cells compared to that in MCF-7 cells. Moreover, β2m mRNA remained undetectable in MCF-7/Adr cells following cycloheximide treatment. However, in MCF-7 cells, increased β2m mRNA was observed after 12 h, and a similar level of increased mRNA expression was observed after 36 h of cycloheximide treatment in MCF-7/Adr-5 cells; these results suggest that one of the mechanisms controlling β2m mRNA expression might be a negative regulatory protein in MCF-7/Adr-5 cells. Analysis of the β2m status of other drug-resistant MCF-7 sublines revealed that deregulation of β2m is not limited to DOX resistance, but can also be detected in cells selected for resistance to mAMSA and DOX-verapamil. In addition, our data show that reduced β2m expression correlates with the decreased levels of estrogen receptor (ER) expression in the DOX-resistant MCF-7/Adr and T-47D/Adr-4 human breast cell lines. Furthermore, we provide evidence that the partial inhibition of β2m by antisense RNA results in 2,3-fold decreased sensitivity of MCF-7 cells to DOX and mAMSA. Moreover, the addition of exogenous β2m protein near its physiological human serum concentration can modulate the DOX sensitivity of the MCF-7 antisense β2m and control transfectants. Therefore, these results indicate that lost or decreased β2m expression is involved in the development of the drug-resistant phenotype and correlates with the loss of ER in human breast cancer cell lines.

UR - http://www.scopus.com/inward/record.url?scp=0032544223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032544223&partnerID=8YFLogxK

U2 - 10.1021/bi980573c

DO - 10.1021/bi980573c

M3 - Article

C2 - 9709006

AN - SCOPUS:0032544223

VL - 37

SP - 11679

EP - 11691

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 33

ER -